Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting

Journal of Managed Care Pharmacy

Volumn 14, Issue 8 SUPPL., 2008, Pages

  Cziraky, Mark J ^a,b   Watson, Karol E ^c,d   Talbert, Robert L ^e,f   Stella, Patti ^g  

^a HEALTHCORE INC   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g Academy for Continued Healthcare Learning   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MANAGED CARE; MATHEMATICAL MODEL; METABOLIC SYNDROME X; MONOTHERAPY; PRACTICE GUIDELINE; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; MANAGED CARE PROGRAMS; RISK MANAGEMENT; TRIGLYCERIDES;

EID: 56049096263     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
2. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-25.
3. Davidson MH. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Am J Manag Care. 2007; 13(Suppl 10):S260-69.
4. Killilea T, Funk L. Cost efficiency and formulary considerations for statin therapy. Am J Manag Care. 2006;12(Suppl 11):S325-31.
5. Hess G, Sanders KN, Hill J, Liu LZ. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care. 2007; 13(Suppl 3):S80-85.
6. Meissner B, Dickson M, Shinogle J, Reeder CE, Belazi D, Senevirante V. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. J Manag Care Pharm. 2006;12(4):331-40. Available at: www.amcp.org/data/jmcp/ formulary_management_331-340.pdf.pdf
7. Ye X, Gross CR, Schommer J, Cline R, Xuan J, St Peter WL. Initiation of statins after hospitalization for coronary heart disease. J Manag Care Pharm. 2007;13(5):385-96. Available at: www.amcp.org/data/jmcp/ JMCPMaga_June%2007_p385-396.pdf
8. Gazmararian JA, Kripalani S, Miller MJ, Echt KV, Ren J, Rask K. Factors associated with medication refill adherence in cardiovascular-related diseases: a focus on health literacy. J Gen Intern Med. 2006;21(12):1215-21.
9. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care. 2005;28(3):595-99.
10. Insull W, Jr., Ghali JK, Hassman DR, JW YA, Gandhi SK, Miller E. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc. 2007;82(5):543-50.
11. Nag SS, Daniel GW, Bullano MF, et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm. 2007;13(8):652-63. Available at: www.amcp.org/data/jmcp/JMCPMaga_652-663.pdf
12. Hoerger TJ, Ahmann AJ. The impact of diabetes and associated cardio-metabolic risk factors on members: strategies for optimizing outcomes. J Manag Care Pharm. 2008;14(1 Suppl C):S2-18. Available at: www.amcp.org/data/jmcp/JMCPSuppC_Feb08.pdf
13. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-146.
14. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15): 1495-04.
15. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J. Med. 2005;352(14):1425-35.
16. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294(19):2437-45.
17. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77(14):1179-84.
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-21.
19. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39.
20. Charland SL, Quimbo R, Cziraky MJ, Weathermon RA, Stanek EJ. Modeled achievement of optimal lipid values and associated cardiovascular event rates with extended-release niacin/simvastatin, ezetimibe/simvastatin, and individual agents in a managed care population. (poster) Value Health. 2007;10:A56.
21. Stanek EJ, Charland SL, Weathermon RA, Quimbo RA, Cziraky MJ. Diabetes mellitus population modeling of lipid goal achievement with extended-release niacin/simvastatin versus other high-potency agents. (poster) American Diabetes Association 67th Scientific Sessions. Chicago, IL; 2007. Abstract 2445-PO. Available at: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID= 55899
22. Stanek EJ, Quimbo RA, Cziraky MJ, Weathermon RA, Charland SL. Population-based response estimates for extended-release niacin/ simvastatin versus other high-potency dyslipidemia therapy in patients with the metabolic syndrome. (poster) Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference. Chicago, IL; 2007. Abstract P438. Arterioscler Throm Vasc Biol. 2007;27(6):e-114.
23. Zhang B, Friedman M, Charland SL, Burge RT, Simko RJ, Menzin J. A model-based analysis of the effects of intensifying lipid-altering therapy on direct medical costs of coronary heart disease events in a secondary prevention population in the United States. (poster) Value Health. 2007;10:A411.
24. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006;5(4):295-309.
25. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol. 2008;2:79-90.
26. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs. simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008;101:1428-36.
27. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-89.
28. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349-57.
29. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
30. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20): 1615-22.
31. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-1009.
32. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-07.
33. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction.J Am Coll Cardiol. 2005;46(7):1225-28.
34. Miller M, Cannon CE, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008; 51(7):724-30.
35. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991; 67(15):1185-89.
36. Genest JJ, Jr., Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85(6):2025-2033.
37. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-59.
38. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995; 91(9):2488-96.
39. Assmann C, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med. 2003;54:321-41.
40. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004;20(8):1253-68.
41. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8-15.
42. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol. 1983;52:9B-12B.
43. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47.
44. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol. 1988;4(Suppl A):5A-10A.
45. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007; 357(13):1301-10.
46. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 western prospective studies. Circulation. 2007; 115(4):450-58.
47. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413-19.
48. Jiang R, Schulze MB, Li T, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care. 2004;27(8):1991-97.
49. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28(8):1916-21.
50. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326-33.
51. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98(10):1363-68.
52. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106(20):2526-29.
53. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162-72.
54. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31(Suppl 1):S12-54.
55. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-72.
56. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care. 2007;30(Suppl 1):S4-41.
57. Brown WV. Expert commentary: the safety of fibrates in lipid-lowering therapy. Am J Cardiol. 2007;99(6A):19C-21C.
58. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99(6A):22C-31C.
59. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patient at high risk for coronary events. N Engl J Med. 2007;357(21):2109-22.
60. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(4):360-81.
61. Canner FL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2005;95:254-57.
62. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999,341(6):410-18.
63. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels apolipoprotein B. N Engl J Med. 1990;323(19):1289-98.
64. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583-92.
65. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol. 2006;17(6):631-36.
66. Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol. 2004;93(3):307-12.
67. Brown BG, Cheung MC, Lee AC, Zhao XQ, Chait A. Antioxidant vitamins and lipid therapy: end of a long romance? Arterioscler Thromb Vasc Biol. 2002;22(10):1535-46.
68. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol. 2001;21(8):1320-26.
69. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-17.
70. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22(11):2243-50.
71. Cannon CP. Combination therapy in the management of mixed dyslipidaemia. J Intern Med. 2008;263(4):353-365.
72. HPS2-THRIVE: Treatment of High-Density Lipoprotein to Reduce the Incidence of Vascular Events. Available at: http://controlled-trials.com/ isrctn/pf/29503772
73. ClinicalTrials.gov. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. Available at: www.clinicaltrials.gov/ct2/show/ NCT00461630
74. Devine PJ, Turco MA, Taylor AJ. Design and Rationale of the ARBITER 6 Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS). Cardiovasc Drugs Ther. 2007;21(3):221-25.
75. Stockl K, Tjioe D, Gong S, Stroup J, Harada A, Zhang S. Increased statin use in MTMP members with diabetes or coronary artery disease following implementation of a provider-based statin initiation intervention. (poster) J Manag Care Pharm. 2008;14(2):252. Available at: www.amcp.org/data/jmcp/JMCPMaga_March%2008_205-252.pdf
76. Alsheikh-Ali AA, Lin JL, Abourjaily F, Ahearn D, Kuvin JT, Karas RH. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol. 2006;98(9):1231-33.
77. Zachry W, Martin E, Hume A. Contrasting case-mix characteristics of patients treated with niacin extended release and fenofibrate in a large managed care dataset. ASHP Midyear Clinical Meeting. Las Vegas, NV; 2007.
78. Charland SL, Cziraky MJ, Quimbo R, et al. Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. J Clin Lipidol. In press.
79. Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin. 2007;23(3):553-63.
80. Rosenzweig JL, Weinger K, Poirier-Solomon L, Rushton M. Use of a disease severity index for evaluation of healthcare costs and management of comorbidities of patients with diabetes mellitus. Am J Manag Care. 2002;8(11):950-58.
81. Cziraky MJ, Quimbo R, Sarawate C, Burge RT, Simko RJ. Simultaneous attainment of multiple lipid fraction target levels in 10,303 patients with type-2 diabetes mellitus (DM). (poster) American Diabetes Association 67th Annual Scientific Sessions. Chicago, IL; 2007. Abstract 0908-P. Available at: http://professiona1.diabetes.org/ Abstracts_Display.aspx?TYP=1&CID=55008
82. Simko RJ, Cziraky MJ, Quimbo R, Sarawate C, Burge RT. The effects of multiple lipid goal attainment on cardiovascular events and costs. (poster) National Lipid Association Annual Meeting. Scottsdale, AZ; 2007. Abstract 406.
83. Bangalore S, Shahane A, Parkar S, Messerli FH. Compliance and fixed-dose combination therapy. Curr Hypertens Rep. 2007;9(3):184-89.
84. Valenti WM. Expanding role of conformulations in the treatment of HIV infection: impact of fixed-dose combinations. AIDS Read. 2004;14(10);541-43, 547-50.
85. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64(12):1279-83.
86. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24(3):460-67.